Regulation of prolactin secretion by dopamine at the level of the hypothalamus in the turkey.
Avian prolactin (PRL) secretion is regulated by vasoactive intestinal peptide (VIP) neurons residing in the infundibular nuclear complex (INF) of the hypothalamus. This VIPergic activity is modulated by stimulatory dopaminergic inputs. Dynorphin, serotonin (5-HT), dopamine (DA) and VIP all appear to stimulate PRL secretion along a hypothalamic pathway, expressing kappa opioid, serotonergic, dopaminergic and VIPergic receptors in succession, with the VIPergic system as the final mediator. Electrical stimulation (ES) within the turkey hypothalamus at the level of the medial preoptic area (POA), the ventromedial hypothalamic nucleus (VMN), the INF or the median eminence (ME) results in the release of PRL. When the selective D(1) DA receptor antagonist SCH-23390 HCl was infused intraventricularly at the rate of 10 nmol/min, ES in the POA or VMN was unable to increase PRL levels, while ES in the INF and ME did increase PRL to the same level as that of controls. These results were interpreted to suggest that the D(1) DA receptors involved in PRL release lie caudally to the VMN and dorsally to the INF. Bilateral microinjections (50 ng) of the D(1) DA receptor agonist SKF-38393 HCl into the POA or VMN failed to produce any increase in PRL, while similar microinjections in the INF increased PRL significantly within 15 min. Bilateral microinjections of the D(1) DA antagonist (50 ng) into the INF blocked the rise in PRL associated with ES in the POA. Bilateral microinjections of a D(2) DA antagonist (50 ng) into the INF failed to block PRL secretion induced by ES in the POA. Tract tracing, using double-label immunocytochemistry, revealed the presence of a monosynaptic dopaminergic pathway projecting from the POA to the INF. These data imply that the only hypothalamic D(1) DA receptors involved in the regulation of avian PRL secretion are those residing within the INF in the same region as the VIP neurons known to be involved in PRL secretion.
Youngren
Orlan
O
Department of Animal Science, 495 Animal Science/Veterinary Medicine Building, University of Minnesota, 1988 Fitch Avenue, St. Paul, MN 55108, USA. young019@umn.edu
Chaiseha
Yupaporn
Y
Al-Zailaie
Khaled
K
Whiting
Stephen
S
Kang
Seong Wook
SW
El Halawani
Mohamed
M
D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D001552:Benzazepines / Q000008:administration & dosage / Q000494:pharmacology; D004298:Dopamine / Q000494:pharmacology*; D004558:Electric Stimulation; D007031:Hypothalamus / Q000187:drug effects* / Q000502:physiology*; D007033:Hypothalamus, Middle / Q000187:drug effects; D007150:Immunohistochemistry; D007700:Kinetics; D008845:Microinjections; D011301:Preoptic Area / Q000187:drug effects; D011388:Prolactin / Q000378:metabolism*; D014660:Vasoactive Intestinal Peptide / Q000378:metabolism
D001552:Benzazepines; D014660:Vasoactive Intestinal Peptide; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D011388:Prolactin; D004298:Dopamine